LIVMARLI® Global Availability
The first approved treatment for cholestatic pruritus in patients with Alagille syndrome (ALGS).
LIVMARLI has also been approved by the FDA for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) five years of age and older. See where LIVMARLI is now approved.*
*Approval through country regulatory agencies; commercialized by Mirum or partner/distributor.
Alagille syndrome (ALGS)
Cholestatic pruritus in ALGS patients three months and older
Prescribing Information and Important Safety InformationEuropean Union
Cholestatic pruritus in ALGS patients two months and older
SMPCCanada
Cholestatic pruritus in ALGS patients
- Pediatrics (12 months to 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LIVMARLI in these pediatric patients have been established. Therefore, Health Canada has authorized an indication for pediatric use.
- Pediatrics (<12 months): The safety and efficacy of LIVMARLI in these pediatric patients have not been established.
China1
Cholestatic pruritus in ALGS patients one year
and older
Israel2
Cholestatic pruritus in ALGS patients one year
and older
South Korea3
Cholestatic pruritus in ALGS patients one year
and older
1. Approved through country regulatory agencies; commercialized by partner, CANbridge.
2. Approved through country regulatory agencies; commercialized by distributor partner, Neopharm.
3. Approved through country regulatory agencies; commercialized by partner, GC Pharma.
Progressive familial intrahepatic cholestasis (PFIC)
Cholestatic pruritus in PFIC patients five years of age and older
LIVMARLI is not for use in patients with PFIC type 2 who have a severe defect in the bile salt export pump (BSEP) protein
Prescribing information and important safety information
